Nephro-Urology Monthly

Published by: Kowsar

Serum Cystatin C as a Marker of Renal Function in Critically Ill Patients With Normal Serum Creatinine

Mohammad Mahdi Sagheb 1 , Soha Namazi 2 , Bita Geramizadeh 3 , Amin Karimzadeh 4 , Mohammad Bagher Oghazian 5 and Iman Karimzadeh 5 , *
Authors Information
1 Nephrology Urology Research Center and Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 Department of Clinical Pharmacy, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, IR Iran
3 Transplant Research Center and Department of Pathology, Shiraz University of Medical Sciences, Shiraz, IR Iran
4 Department of Dermatology, Imam Khomeini Hospital, Jundishapur University of Medical Sciences, Ahvaz, IR Iran
5 Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IR Iran
Article information
  • Nephro-Urology Monthly: March 01, 2014, 6 (2); e26784
  • Published Online: March 1, 2014
  • Article Type: Research Article
  • Received: October 2, 2013
  • Revised: October 24, 2013
  • Accepted: December 7, 2013
  • DOI: 10.5812/numonthly.15224

To Cite: Sagheb M M, Namazi S, Geramizadeh B, Karimzadeh A, Bagher Oghazian M, et al. Serum Cystatin C as a Marker of Renal Function in Critically Ill Patients With Normal Serum Creatinine, Nephro-Urol Mon. 2014 ; 6(2):e26784. doi: 10.5812/numonthly.15224.

Abstract
Copyright © 2014, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Kunzendorf U, Haase M, Rolver L, Haase-Fielitz A. Novel aspects of pharmacological therapies for acute renal failure. Drugs. 2010; 70(9): 1099-114[DOI][PubMed]
  • 2. Kellum JA, Angus DC, Johnson JP, Leblanc M, Griffin M, Ramakrishnan N, et al. Continuous versus intermittent renal replacement therapy: a meta-analysis. Intensive Care Med. 2002; 28(1): 29-37[DOI][PubMed]
  • 3. Kellum JA, Levin N, Bouman C, Lameire N. Developing a consensus classification system for acute renal failure. Curr Opin Crit Care. 2002; 8(6): 509-14[PubMed]
  • 4. Bellomo R, Kellum JA, Ronco C. Defining acute renal failure: physiological principles. Intensive Care Med. 2004; 30(1): 33-7[DOI][PubMed]
  • 5. Hoste EA, Damen J, Vanholder RC, Lameire NH, Delanghe JR, Van den Hauwe K, et al. Assessment of renal function in recently admitted critically ill patients with normal serum creatinine. Nephrol Dial Transplant. 2005; 20(4): 747-53[DOI][PubMed]
  • 6. Filler G, Bokenkamp A, Hofmann W, Le Bricon T, Martinez-Bru C, Grubb A. Cystatin C as a marker of GFR--history, indications, and future research. Clin Biochem. 2005; 38(1): 1-8[DOI][PubMed]
  • 7. Royakkers AA, van Suijlen JD, Hofstra LS, Kuiper MA, Bouman CS, Spronk PE, et al. Serum cystatin C-A useful endogenous marker of renal function in intensive care unit patients at risk for or with acute renal failure? Curr Med Chem. 2007; 14(21): 2314-7[PubMed]
  • 8. Bokenkamp A, Ozden N, Dieterich C, Schumann G, Ehrich JH, Brodehl J. Cystatin C and creatinine after successful kidney transplantation in children. Clin Nephrol. 1999; 52(6): 371-6[PubMed]
  • 9. Le Bricon T, Thervet E, Benlakehal M, Bousquet B, Legendre C, Erlich D. Changes in plasma cystatin C after renal transplantation and acute rejection in adults. Clin Chem. 1999; 45(12): 2243-9[PubMed]
  • 10. Hermida J, Romero R, Tutor JC. Relationship between serum cystatin C and creatinine in kidney and liver transplant patients. Clin Chim Acta. 2002; 316(1-2): 165-70[PubMed]
  • 11. Lapointe V, Jocov D, Denault A. Hemodynamic instability in septic shock. Can J Anaesth. 2009; 56(11): 864-7[DOI][PubMed]
  • 12. Shi GP, Sukhova GK, Grubb A, Ducharme A, Rhode LH, Lee RT, et al. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest. 1999; 104(9): 1191-7[DOI][PubMed]
  • 13. Fricker M, Wiesli P, Brandle M, Schwegler B, Schmid C. Impact of thyroid dysfunction on serum cystatin C. Kidney Int. 2003; 63(5): 1944-7[DOI][PubMed]
  • 14. Jayagopal V, Keevil BG, Atkin SL, Jennings PE, Kilpatrick ES. Paradoxical changes in cystatin C and serum creatinine in patients with hypo- and hyperthyroidism. Clin Chem. 2003; 49(4): 680-1[PubMed]
  • 15. Bjarnadottir M, Grubb A, Olafsson I. Promoter-mediated, dexamethasone-induced increase in cystatin C production by HeLa cells. Scand J Clin Lab Invest. 1995; 55(7): 617-23[DOI][PubMed]
  • 16. Brenner BM. Brenner and Rector's The Kidney. 2008;
  • 17. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985; 13(10): 818-29[PubMed]
  • 18. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1): 31-41[PubMed]
  • 19. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130(6): 461-70[PubMed]
  • 20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol. 2000; 11[PubMed]
  • 21. Dennen P, Douglas IS, Anderson R. Acute kidney injury in the intensive care unit: an update and primer for the intensivist. Crit Care Med. 2010; 38(1): 261-75[DOI][PubMed]
  • 22. Zhang Z, Lu B, Sheng X, Jin N. Cystatin C in prediction of acute kidney injury: a systemic review and meta-analysis. Am J Kidney Dis. 2011; 58(3): 356-65[DOI][PubMed]
  • 23. Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, et al. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int. 1995; 47(1): 312-8[PubMed]
  • 24. Stickle D, Cole B, Hock K, Hruska KA, Scott MG. Correlation of plasma concentrations of cystatin C and creatinine to inulin clearance in a pediatric population. Clin Chem. 1998; 44(6 Pt 1): 1334-8[PubMed]
  • 25. Randers E, Kristensen JH, Erlandsen EJ, Danielsen H. Serum cystatin C as a marker of the renal function. Scand J Clin Lab Invest. 1998; 58(7): 585-92[PubMed]
  • 26. Risch L, Blumberg A, Huber A. Rapid and accurate assessment of glomerular filtration rate in patients with renal transplants using serum cystatin C. Nephrol Dial Transplant. 1999; 14(8): 1991-6[PubMed]
  • 27. Xu H, Lu Y, Teng D, Wang J, Wang L, Li Y. Assessment of glomerular filtration rate in renal transplant patients using serum cystatin C. Transplant Proc. 2006; 38(7): 2006-8[DOI][PubMed]
  • 28. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002; 40(2): 221-6[DOI][PubMed]
  • 29. Khorgami Z, Abdollahi A, Soleimani S, Ahamadi F, Mahdavi-Mazdeh M. Relationship between serum cystatin C and creatinine or dialysis adequacy in patients on chronic maintenance hemodialysis. Nephrourol Mon. 2013; 5(2): 733-5[DOI][PubMed]
  • 30. Delanaye P, Lambermont B, Chapelle JP, Gielen J, Gerard P, Rorive G. Plasmatic cystatin C for the estimation of glomerular filtration rate in intensive care units. Intensive Care Med. 2004; 30(5): 980-3[DOI][PubMed]
  • 31. Le Bricon T, Leblanc I, Benlakehal M, Gay-Bellile C, Erlich D, Boudaoud S. Evaluation of renal function in intensive care: plasma cystatin C vs. creatinine and derived glomerular filtration rate estimates. Clin Chem Lab Med. 2005; 43(9): 953-7[DOI][PubMed]
  • 32. Herrero-Morin JD, Malaga S, Fernandez N, Rey C, Dieguez MA, Solis G, et al. Cystatin C and beta2-microglobulin: markers of glomerular filtration in critically ill children. Crit Care. 2007; 11(3)[DOI][PubMed]
  • 33. Villa P, Jimenez M, Soriano MC, Manzanares J, Casasnovas P. Serum cystatin C concentration as a marker of acute renal dysfunction in critically ill patients. Crit Care. 2005; 9(2)-43[DOI][PubMed]
  • 34. Ahlstrom A, Tallgren M, Peltonen S, Pettila V. Evolution and predictive power of serum cystatin C in acute renal failure. Clin Nephrol. 2004; 62(5): 344-50[PubMed]
  • 35. Mazul-Sunko B, Zarkovic N, Vrkic N, Antoljak N, Bekavac Beslin M, Nikolic Heitzler V, et al. Proatrial natriuretic peptide (1-98), but not cystatin C, is predictive for occurrence of acute renal insufficiency in critically ill septic patients. Nephron Clin Pract. 2004; 97(3)-7[DOI][PubMed]
  • 36. Royakkers AA, Korevaar JC, van Suijlen JD, Hofstra LS, Kuiper MA, Spronk PE, et al. Serum and urine cystatin C are poor biomarkers for acute kidney injury and renal replacement therapy. Intensive Care Med. 2011; 37(3): 493-501[DOI][PubMed]
  • 37. Herget-Rosenthal S, Marggraf G, Husing J, Goring F, Pietruck F, Janssen O, et al. Early detection of acute renal failure by serum cystatin C. Kidney Int. 2004; 66(3): 1115-22[DOI][PubMed]
  • 38. Nejat M, Pickering JW, Walker RJ, Endre ZH. Rapid detection of acute kidney injury by plasma cystatin C in the intensive care unit. Nephrol Dial Transplant. 2010; 25(10): 3283-9[DOI][PubMed]
  • 39. Nejat M, Pickering JW, Walker RJ, Westhuyzen J, Shaw GM, Frampton CM, et al. Urinary cystatin C is diagnostic of acute kidney injury and sepsis, and predicts mortality in the intensive care unit. Crit Care. 2010; 14(3)[DOI][PubMed]
  • 40. Brochard L, Abroug F, Brenner M, Broccard AF, Danner RL, Ferrer M, et al. An Official ATS/ERS/ESICM/SCCM/SRLF Statement: Prevention and Management of Acute Renal Failure in the ICU Patient: an international consensus conference in intensive care medicine. Am J Respir Crit Care Med. 2010; 181(10): 1128-55[DOI][PubMed]
  • 41. Seller-Perez G, Herrera-Gutierrez ME, Banderas-Bravo E, Olalla-Sanchez R, Lozano-Saez R, Quesada-Garcia G. [Concordance in critical patients between the equations designed for the calculation of glomerular filtration rate and 24-hour creatinine clearance]. Med Intensiva. 2010; 34(5): 294-302[DOI][PubMed]
  • 42. Larsson A, Flodin M, Hansson LO, Carlsson L. Patient selection has a strong impact on cystatin C and Modification of Diet in Renal Disease (MDRD) estimated glomerular filtration rate. Clin Biochem. 2008; 41(16-17): 1355-61[DOI][PubMed]
  • 43. Lipcsey M, Furebring M, Rubertsson S, Larsson A. Significant differences when using creatinine, modification of diet in renal disease, or cystatin C for estimating glomerular filtration rate in ICU patients. Ups J Med Sci. 2011; 116(1): 39-46[DOI][PubMed]
  • 44. Wulkan R, den Hollander J, Berghout A. Cystatin C: unsuited to use as a marker of kidney function in the intensive care unit. Crit Care. 2005; 9(5): 531-2[DOI][PubMed]
  • 45. Wiesli P, Schwegler B, Spinas GA, Schmid C. Serum cystatin C is sensitive to small changes in thyroid function. Clin Chim Acta. 2003; 338(1-2): 87-90[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments